Disease Control App for Doctors Wins Health 2.0 Data Challenge, Ana... ( SAN FRANCISCO March 22 2011 /- htt.....)

Disease Control App for Doctors Wins Health 2.0 Data Challenge, Analyze This!

Date:3/22/2011

SAN FRANCISCO, March 22, 2011 /PRNewswire/ -- Practice Fusion has named Epicenter the winner of Analyze This! part of Health 2.0's Spring Developer Challenge. Using Practice Fusion's sample of 15,000 de-identified health records, available free through Microsoft's Windows Azure Marketplace, Epicenter developer and self-confessed "data nerd," John Schrom, said his application could help identify and better control the spread of disease across America.

(Logo: http://photos.prnewswire.com/prnh/20091118/PFLOGO)

"Epicenter allows doctors to benchmark local patient data against a uniform dataset to identify anomalies in real-time," said Schrom. "It would also allow doctors to quickly identify local disease outbreaks, the groups they're occurring in, and then share those high-risk patient profiles with the wider medical community to drive proactive treatment initiatives, more targeted screening and faster warnings." A video demonstration of Schrom's Epicenter application can be viewed here.

As part of the Health 2.0 and US Department of Health and Human Services' (HHS) Developer Challenge, Analyze This! entrants were asked to use Practice Fusion's dataset to answer pressing public health questions around obesity trends, drug efficacy, disease outbreaks and treatment outcomes.

Schrom, a 26 year old epidemiologist with Hennepin County Medical Center in Minneapolis, believes increased access to de-identified patient data is critical to the development of potentially lifesaving healthcare informatics tools, like Epicenter.

"De-identified patient data is the best way to find health trends that would be m
'/>"/>

SOURCE Practice Fusion
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
2. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
3. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
4. VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
5. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
6. Integrated Prevention Demonstration Campaign Launched in Western Kenya to Fight HIV, Malaria and Diarrhoeal Disease
7. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
8. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
9. Massachusetts Company May Have Silver Bullet In Vitamin D Fight Against Disease
10. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
11. Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval)

Post Your Comments:

(Date:6/18/2013)... June 18, 2013 Tabletop SEMs are ... SEMs but have limited performance and capability such as ... size SEMs would normally provide better imaging performance and ... operate and have a higher cost of maintenance. ... gap between these two types of SEM product, offering ...

(Date:6/18/2013)... HONG KONG, June 18, 2013 China Cord ... the "Company"), China,s leading provider of cord blood collection, ... storage services, today announced its preliminary unaudited financial results ... year 2013 ended March 31, 2013. ... for the fourth quarter of fiscal 2013 increased by ...

(Date:6/18/2013)... Angeles, CA (PRWEB) June 18, 2013 (PRWEB) June ... construction’s #1 time and attendance system in North ... software that shares employee data and payroll records ... AccountLinx Plus automates ExakTime software setup ... The software imports employee data from a business’ ...

(Date:6/18/2013)... Demanding industrial and environmental conditions are ... Sapphire and Glass Ball Lenses, now available in an ... Company , of Philadelphia , PA. , Optical Ball ... light beams without the need for direct physical contact. ... (9 mohs) make it the ideal choice for fiber-optic ...

[0] Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes [0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] ExakTime Introduces AccountLinx Plus [0] Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors

... BAX ) announced today that its Board of ... of the company,s,common stock to be executed upon completion ... less than $700 million of remaining authorization under its,previous ... March,2007. Shares will be repurchased in the open market ...

... 18 /PRNewswire/ - Aegera Therapeutics announced today,the ... trial for AEG33773, a,novel, orally bioavailable small ... diabetic neuropathy. The Phase I study will ... AEG33773 using a randomized,double blind, placebo controlled, ...

... siRNA Targeting of, VEGF Expression, Further Strengthening OPKO,s RNAi Intellectual Property ... ... OPKO Health, Inc. (Amex: OPK ),today announced that it has been ... for methods related to the use and,administration of small interfering RNAs (siRNAs) ...

Cached Biology Technology:Baxter's Board of Directors Approves New Share Repurchase Authorization of $2 Billion 2 Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain 2 OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 2 OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 3 OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 4

Baxter's Board of Directors Approves New Share Repurchase Authorization of $2 Billion Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib

(Date:6/19/2013)... new variety of canary seeds bred specifically for human ... ideal for people with celiac disease (CD), scientists have ... of Agricultural and Food Chemistry . , Joyce ... 3 million people in the United States alone have ... wheat, barley, rye and other grains that contain gluten-related ...

(Date:6/19/2013)... A Cornell University study offers further proof that the ... 6 million years ago was profoundly influenced by mutations ... on and off. , The study, published June 9 ... 40-year-old hypothesis that regulation of genes must play an ... between humans and chimps in the proteins produced by ...

(Date:6/19/2013)... 2013 Elsevier, a world-leading provider of scientific, technical ... announce the launch of a new open access journal, ... GeoResJ , Elsevier,s earth and planetary science journals ... journal aims to provide a forum for rapid publication ... The journal will be co-edited by six Executive Editors, ...

Breaking Biology News(10 mins):New research backs theory that genetic 'switches' play big role in human evolution 2 New research backs theory that genetic 'switches' play big role in human evolution 3

[0] New canary seed is ideal for gluten-free diets in celiac disease [0] New research backs theory that genetic 'switches' play big role in human evolution [0] Elsevier launches open access journal: GeoResJ

... genetic diversity in crops is traditional practice for agriculture ... develop breeding programs with great care for the security ... numerous risks the world,s food supplies face with the ... essential as an insurance against unforeseeable changes in the ...

... -- A Duke University-led team has brought powerful software ... Working together, computer scientists and biochemists have developed and ... to change the machinery that bacteria use to make ... set of computer rules known as the algorithm "K*" ...

... distinguishes itself as the fastest growing greenhouse gas in ... emissions depends on our ability to measure the increase ... increase. Until the late 1950s when high ... whether the industrial revolution and the associated increase in ...

Cached Biology News:Identifying mega-targets for high-yield plant breeding 2 Duke software dramatically speeds enzyme design 2 Duke software dramatically speeds enzyme design 3 Carbon accounting from atmospheric measurements -- the aircraft perspective 2

Identifying mega-targets for high-yield plant breeding Duke software dramatically speeds enzyme design Carbon accounting from atmospheric measurements -- the aircraft perspective

Includes a choice of any 3 EasySep mouse selection kits and EasySep magnet...

... PYREX trypsinizing flasks are used ... into cell suspensions by digestion ... neck accepts cotton plugs. Four ... • Height of Baffles mm ...

... the efficient enrichment of functional endoplasmic ... cell culture. The isolated ER are ... metabolic pathway analysis. Metabolic abnornalities of ... children, cystic fibrosis and many more ...

Plasmid expressing PLAP reporter gene....

Biology Products:

EasySep Mouse Combo Starter, Kit from StemCell Technologies, Inc.Pyrex brand baffled trypsinizing flask, with beaded neck from Sigma-Aldrich Endoplasmic Reticulum Isolation Kit from Sigma-Aldrich pORF-PLAP from InvivoGen